Further Refining Risk in Hypertrophic Cardiomyopathy With Late Gadolinium Enhancement by CMR
- PMID: 30115225
- PMCID: PMC6145095
- DOI: 10.1016/j.jacc.2018.05.063
Further Refining Risk in Hypertrophic Cardiomyopathy With Late Gadolinium Enhancement by CMR
Keywords: fibrosis; gadolinium; hypertrophic cardiomyopathy; magnetic resonance imaging; myectomy.
Comment on
-
Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.J Am Coll Cardiol. 2018 Aug 21;72(8):857-870. doi: 10.1016/j.jacc.2018.05.060. J Am Coll Cardiol. 2018. PMID: 30115224
References
-
- Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. J Am Coll Cardiol HF 2018;6:364–75. - PubMed
-
- Maron BJ, Rowin EJ, Casey SA, Maron MS. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol 2016;1:98–105. - PubMed
-
- Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary. J Am Coll Cardiol 2013;58:2703–38. - PubMed
-
- O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk- SCD). Eur Heart J 2014;35:2010–20. - PubMed
-
- O’Mahony C, Jichi F, Ommen SR, et al. International external validation study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation 2018;137:1015–23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources